A clinical study of the use of roncoleukin, interferon alpha-2b for therapeutic purposes in coronavirus infection was conducted. The high therapeutic activity of roncoleukin, vladonix and interferon in COVID-19 infection, including postcovid syndrome, has been established.

Some COVID-19 patients develop post-COVID syndrome, in the pathogenesis of which there are disorders in the respiratory, immune, and nervous systems. The aim of the study was to evaluate the clinical efficacy of Alvenorm forte and Roncolekin® in patients with post -COVID syndrome undergoing outpatient rehabilitation. The studies were carried out in outpatient clinics in Semey from October 2021 to March 2022. The immunological studies were carried out in the laboratory of the Semey Med ical University. Methods: 26 patients with post-COVID syndrome and 30 donors were included in a controlled, open, non-randomized clinical trial. All patients received the drug Alvenorm forte daily for 30 days and Roncoleukin® 250,000 IU subcutaneously every three days (10-12 injections). The studies of the phenotype of blood cells were carried out by the ELISA method with a set of monoclonal antibodies. All patients with COVID-19 had shortness of breath, tachycardia, and neurological symptoms. High neutrophil count, leukopenia, lymphopenia, monocytopenia, a relative increase in T-helper cells, and a decrease in B and NK cells were observed in the blood. After the rehabilitation, dyspnea and tachycardia disappeared in most patients, with a significant decrease in neurological manifestations. After the rehabilitation, the main indicators of blood and immune status were restored. Conclusions: post-COVID syndrome was accompanied by shortness of breath, tachycardia, neurological symptoms, and immune deficiency. The use of Alvenorm forte and Roncoleukin® made it possible to stop respiratory and immune deficiency, tachycardia, and neurological symptoms. Our data are consistent with the results of immunorehabilitation.